Last update June 10, 2018

Maternal Sjögren syndrome

Compatible

Safe product and/or breastfeeding is the best option.

An autoimmune inflammatory disease affecting the salivary glands, lacrimal glands and other moisture producers that causes irritation and dry mouth and eyes. It can also affect joints, skin, vagina, lung, muscles, liver or kidney (MedlinePlus 2017).
It can be primary or secondary to other inflammatory autoimmune diseases such as rheumatoid arthritis, lupus or scleroderma.

It is much more common (90%) in women. It may worsen (10% of cases) during pregnancy and 5% of newborns may have heart block (Priori 2013).

Like other inflammatory autoimmune diseases, it may be accompanied by Raynaud's Phenomenon in hands (Isenberg 1995), but not usually in nipples.

There may be mild hyperprolactinemia (Jara 2011, Gutiérrez 1994) which has not been found in other observations (Karakus 2017).

The mammary gland is not affected. Normal breastfeeding has been observed in women affected by this disease, with 32% of women still breastfeeding at 6 months and 8% at one year (Priori 2013).

The required treatment is usually topical (artificial tears, ocular and vaginal lubricants, oral salivation stimulants) and are compatible with breastfeeding. If other inflammatory diseases coexist, refer to the required medication.

Expert authors do not contraindicate breastfeeding (Lawrence 2017 p.595).


See below the information of these related products:

  • Azathioprine (Safe product and/or breastfeeding is the best option.)
  • Cyclophosphamide (Unsafe. Moderate/severe adverse effects. Compatible under certain circumstances. Follow-up recommended. Use safer alternative or discontinue breastfeeding from 5 to 7 T ½ . Read Commentary.)
  • Hydroxychloroquine Sulfate (Safe product and/or breastfeeding is the best option.)
  • Hypromellose (Safe product and/or breastfeeding is the best option.)
  • Ibuprofen (Safe product and/or breastfeeding is the best option.)
  • Lupus (Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.)
  • Maternal Rheumatoid arthritis (RA) (Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.)
  • Methotrexate (obstetric and immunosuppressive use) (Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.)
  • Mycophenolate Mofetil (Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.)
  • Non-Hormonal Vaginal Lubricant (Safe product and/or breastfeeding is the best option.)

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.
DONATE NOW

Other names

Maternal Sjögren syndrome is also known as


Maternal Sjögren syndrome in other languages or writings:

Group

Maternal Sjögren syndrome belongs to this group or family:

References

  1. Karakus S, Sahin A, Durmaz Y, Aydin H, Yildiz C, Akkar O, Dogan M, Cengiz A, Cetin M, Cetin A. Evaluation of ovarian reserve using anti-müllerian hormone and antral follicle count in Sjögren's syndrome: Preliminary study. J Obstet Gynaecol Res. 2017 Abstract
  2. MedlinePlus Sjögren syndrome. Medical Encyclopedia 2017 Full text (link to original source) Full text (in our servers)
  3. MedlinePlus. Síndrome de Sjögren. Enciclopedia médica. 2017 Full text (link to original source) Full text (in our servers)
  4. Priori R, Gattamelata A, Modesti M, Colafrancesco S, Frisenda S, Minniti A, Framarino-dei-Malatesta M, Maset M, Quartuccio L, De Vita S, Bartoloni E, Alunno A, Gerli R, Strigini F, Baldini C, Tani C, Mosca M, Bombardieri S, Valesini G. Outcome of pregnancy in Italian patients with primary Sjögren syndrome. J Rheumatol. 2013 Abstract
  5. Jara LJ, Medina G, Saavedra MA, Vera-Lastra O, Navarro C. Prolactin and autoimmunity. Clin Rev Allergy Immunol. 2011 Abstract
  6. Isenberg DA, Black C. ABC of rheumatology. Raynaud's phenomenon, scleroderma, and overlap syndromes. BMJ. 1995 Abstract
  7. Gutiérrez MA, Anaya JM, Scopelitis E, Citera G, Silveira L, Espinoza LR. Hyperprolactinaemia in primary Sjögren's syndrome. Ann Rheum Dis. 1994 Abstract

Total visits

11,039

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2012 of United States of America

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM